05 May 2021 --- Global ingredient manufacturer Kemin Industries has been granted a US patent on the use of its BetaVia’s beta 1,3 glucans for modulating human immune function and treating intestinal inflammation. “Kemin’s new US patent shows our commitment to science and innovation on human health and further explores the benefits and link between immunity and gut health – two of the most valued health areas for consumers worldwide,” Filipa Quintela, marketing manager EMEA at Kemin human nutrition and health, tells NutritionInsight.